Table 2.
Univariate and multivariate analysis of recurrent free survival and overall survival
| Variable | Recurrence-free survival |
Overall survival |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate |
Multivariate |
Univariate |
Multivariate |
||||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Age | 0.996 (0.905−1.096) | 0.936 | 1.001 (0.926−1.082) | 0.979 | |||||
| Sex | |||||||||
| Female | 1.000 | 1.000 | |||||||
| Male | 0.700 (0.283−1.730) | 0.440 | 1.368 (0.640−2.926) | 0.419 | |||||
| Body mass index | 1.050 (0.900−1.225) | 0.533 | 1.016 (0.897−1.151) | 0.802 | |||||
| Charlson comorbidity index | |||||||||
| 3−4 | 1.000 | 1.000 | |||||||
| 5–7 | 0.833 (0.325−2.134) | 0.703 | 0.912 (0.438-1.902) | 0.807 | |||||
| Pathologic grading | |||||||||
| Poorly differentiated, mucinous | 1.686 (0.483−5.887) | 0.413 | 1.689 (0.643-4.438) | 0.288 | |||||
| Others | 1.000 | 1.000 | |||||||
| pT stage | |||||||||
| pT3 | 1.000 | 1.000 | |||||||
| pT4 | 2.579 (0.980−6.786) | 0.055 | 1.522 (0.451−5.134) | 0.498 | 0.639 (0.290−1.408) | 0.267 | |||
| Tumor location | |||||||||
| Right | 1.000 | 1.000 | |||||||
| Left | 1.117 (0.439−2.842) | 0.816 | 1.030 (0.496−2.141) | 0.937 | |||||
| Margin < 5 mm | 0.808 (0.185−3.540) | 0.778 | 1.162 (0.402−3.359) | 0.782 | |||||
| No. of lymph nodes retrieved < 12 | 1.325 (0.407−4.313) | 0.640 | 1.841 (0.767−4.419) | 0.172 | |||||
| Lymphatic invasion | 3.587 (0.805−15.983) | 0.094 | 1.949 (0.360−10.549) | 0.439 | 1.462 (0.588−3.634) | 0.414 | |||
| Venous invasion | 2.550 (1.034−6.289) | 0.042* | 0.859 (0.223−3.304) | 0.825 | 2.739 (1.335−5.620) | 0.006* | 2.313 (0.833−6.427) | 0.108 | |
| Perineural invasion | 6.467 (2.215−18.884) | 0.001* | 4.161 (1.188−14.576) | 0.026* | 6.807 (2.821−16.427) | < 0.001* | 4.760 (1.713−13.226) | 0.003* | |
| Obstruction | 0.680 (0.225−2.052) | 0.494 | 0.693 (0.283−1.699) | 0.423 | |||||
| Perforation | 1.594 (0.208−12.195) | 0.653 | 0.046 (0.000−89.667) | 0.425 | |||||
| Preoperative serum CEA level | 0.997 (0.978−1.017) | 0.759 | 0.996 (0.980−1.012) | 0.593 | |||||
| No. of adverse features | |||||||||
| 1–2 | 1.000 | 1.000 | |||||||
| 3–5 | 4.627 (1.818−11.777) | 0.001* | 3.305 (0.799−13.671) | 0.099 | 2.376 (1.159−4.872) | 0.018* | 1.079 (0.360−3.233) | 0.892 | |
| Adjuvant chemotherapya | 0.435 (0.165−1.145) | 0.092 | 0.317 (0.114−0.882) | 0.028* | 0.555 (0.261−1.181) | 0.127 | 0.487 (0.221−1.071) | 0.074 | |
HR, hazard ratio; CI, confidence interval; pT stage, pathologic T stage; CEA, carcinoembryonic antigen.
a
Defined as completion of more than 80% of the planned adjuvant chemotherapy cycle.
*
P<0.05.